Production (Stage)
Mineralys Therapeutics, Inc.
MLYS
$16.12
$0.503.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -42.21M | -48.95M | -56.34M | -41.01M | -31.51M |
| Total Depreciation and Amortization | 15.00K | 15.00K | 11.00K | 9.00K | 8.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.60M | 1.80M | 427.00K | 25.00K | -318.00K |
| Change in Net Operating Assets | -5.89M | -19.71M | 5.72M | 10.83M | 12.68M |
| Cash from Operations | -45.49M | -66.84M | -50.19M | -30.15M | -19.14M |
| Capital Expenditure | -- | 0.00 | -37.00K | 0.00 | -59.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -92.88M | 83.57M | 79.64M | 7.74M | -55.89M |
| Cash from Investing | -92.88M | 83.57M | 79.61M | 7.74M | -55.95M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 189.29M | 137.00K | 40.00K | 132.00K | 116.27M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -10.00K | -47.00K | -41.00K | -284.00K | -63.00K |
| Cash from Financing | 189.28M | 90.00K | -1.00K | -152.00K | 116.21M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 50.92M | 16.82M | 29.42M | -22.56M | 41.11M |